Publicação científica trimestral do CREMERJ

44 Tratamento do diabetes tipo 2: tendências atuais Alessandra Saldanha de Mattos Matheus Med. Ciên. e Arte , Rio de Janeiro, v.1, n.1, p.25-44, jan-mar 2022 58. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019; 380 (4):347-57. 59. Wiviott SD, Raz I, Bonaca MP. DECLARE–TIMI 58 Investigators et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357. 60. DAPA HF – McMurray JJ, Solomon SD, Inzucchi SE. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381:1995-2008. 61. Blair HA, Keating GM. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus. Drugs. 2016; 76 (3):363-74. 62- Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol. 2013 Oct. 1 (2):123-31. 63. Pieber TR, Marso SP, McGuire DK et al. DEVOTE 3: Temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 2018; 61: 58-65. 64. Sands AT, Zambrowicz BP, Rosenstock J et al. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015; 38(7):1181-8. 65. Frias JP, Davies MJ, Rosenstock J et al. for the SURPASS-2 Investigators* Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021; 385:503-15. 66. Rosenstock J, Wysham C, Frías JP et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Lancet 2021; 398: 143-55.